机译:在多发性骨髓瘤中优化基于树突细胞的免疫疗法:结节内注射独特型脉冲CD40配体成熟的疫苗可诱导患者诱发1型和细胞毒性T细胞免疫反应
Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX;
Myeloma Institute for Research and Therapy;
Myeloma Institute for Research and Therapy;
Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX;
Myeloma Institute for Research and Therapy;
Department of Radiology, University of Arkansas for Medical Science, Little Rock, AR;
Myeloma Institute for Research and Therapy;
Myeloma Institute for Research and Therapy;
Division of Hematology, Blood/Marrow Transplant and Myeloma Program, University of Utah, Salt Lake City, Utah, USA;
Myeloma Institute for Research and Therapy;
dendritic cells; idiotype; vaccination; intranodal; multiple myeloma;
机译:在多发性骨髓瘤中优化基于树突细胞的免疫疗法:结节内注射独特型脉冲CD40配体成熟的疫苗可诱导患者诱发1型和细胞毒性T细胞免疫反应。
机译:自体独特型脉冲树突状细胞接种疫苗后,I期多发性骨髓瘤患者的细胞免疫应答诱导。
机译:自体干细胞移植后,免疫调节药物改善了多发性骨髓瘤患者基于树突细胞的免疫疗法的免疫环境。
机译:优化多发性细胞基瘤中的树突式细胞疗法:异型脉冲CD40配体植物疫苗的肿瘤内注射导致患者1型和细胞毒性T细胞免疫反应的诱导
机译:两种类型的树突状细胞作为辅助介绍的辅助剂介绍,介入骨膜内注射术后人类特异性T细胞应答